Related Experiment Video
Updated: Oct 13, 2025
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
Rapid response of locally advanced oral squamous cell carcinoma to apatinib: A case report
Jian He1,2, Yangyang Zhang1,2, Jin Gao1,2
1Department of Radiation Oncology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui Province, 230031, People's Republic of China.
Abstract:
There are no effective therapeutic options for locally advanced head and neck squamous cell carcinoma (HNSCC). Additionally, there is no standard therapy for patients subjected to multiple lines of treatment. Angiogenesis plays a key role in tumor growth and metastasis. Therefore, inhibition of tumor angiogenesis is an important strategy for tumor therapy. Apatinib is a novel tyrosine kinase inhibitor that inhibits angiogenesis by targeting vascular endothelial growth factor receptor-2 (VEGFR-2). The effect of apatinib on HNSCC has not been clearly established. In this study, we administered apatinib in combination with anti-epidermal growth factor receptor (EGFR) targeted and systemic chemotherapy for the treatment of oral cancer and to achieve better disease outcomes. To avoid fatal bleeding, after achieving good clinical outcomes, the follow-up treatment plan was adjusted. The efficacy of apatinib combined with anti-EGFR targeted and systemic chemotherapy for the treatment of oral cancer has not been previously reported. Our findings show the therapeutic potential of apatinib for advanced HNSCC patients with multiple lines of chemotherapy, especially for patients with large neck masses.
Insights
Apatinib shows promise for advanced head and neck squamous cell carcinoma (HNSCC) when combined with chemotherapy. This combination therapy offers a new option for patients with oral cancer, particularly those with large neck masses.
Area of Science:
- Oncology
- Pharmacology
Background:
- Locally advanced head and neck squamous cell carcinoma (HNSCC) lacks effective therapeutic options, especially for patients who have undergone multiple treatments.
- Tumor angiogenesis, driven by vascular endothelial growth factor receptor-2 (VEGFR-2), is crucial for HNSCC growth and metastasis.
- Apatinib, a novel tyrosine kinase inhibitor, targets VEGFR-2 to inhibit angiogenesis.
Observation:
- This study investigated apatinib combined with anti-epidermal growth factor receptor (EGFR) therapy and systemic chemotherapy for oral cancer.
- The treatment aimed to improve outcomes in advanced HNSCC patients, with careful monitoring to prevent bleeding complications.
- The combination therapy's efficacy in oral cancer had not been previously reported.
Findings:
- Apatinib combined with anti-EGFR targeted therapy and chemotherapy demonstrated therapeutic potential in advanced HNSCC.
- This approach showed particular benefit for patients with large neck masses who had received multiple prior chemotherapy lines.
- The study successfully adjusted treatment plans post-outcome achievement to mitigate risks like fatal bleeding.
Implications:
- Apatinib offers a potential new treatment strategy for advanced HNSCC patients resistant to standard therapies.
- The findings suggest that combining apatinib with chemotherapy and anti-EGFR agents could improve disease outcomes.
- Further research is warranted to establish optimal dosing and long-term safety profiles for this combination therapy in HNSCC.
More Related Videos
06:08Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma
Published on: June 2, 2023
07:29Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
